The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 21, 2020
Filed:
Jan. 18, 2019
Applicant:
Pop Test Oncology Llc, Cliffside Park, NJ (US);
Inventors:
Randice Lisa Altschul, Cliffside Park, NJ (US);
Neil David Theise, New York, NY (US);
Myron Rapkin, Indianapolis, IN (US);
Rebecca O'Brien, Shell Knob, MO (US);
Assignee:
POP TEST ONCOLOGY LLC, Cliffside Park, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/58 (2006.01); A61K 45/06 (2006.01); B65D 75/00 (2006.01); B65D 75/36 (2006.01); A61J 1/10 (2006.01); A61N 5/10 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/107 (2006.01); A61K 47/42 (2017.01); A61K 47/44 (2017.01); A61K 31/337 (2006.01); C07J 17/00 (2006.01); A61K 38/09 (2006.01); A61K 9/00 (2006.01); A61K 51/00 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
A61K 31/58 (2013.01); A61J 1/10 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/107 (2013.01); A61K 31/337 (2013.01); A61K 38/09 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 47/42 (2013.01); A61K 47/44 (2013.01); A61K 51/00 (2013.01); A61N 5/1001 (2013.01); B65D 75/002 (2013.01); B65D 75/36 (2013.01); B65D 75/367 (2013.01); C07J 17/00 (2013.01); G01N 33/743 (2013.01); G01N 2333/575 (2013.01); G01N 2800/56 (2013.01);
Abstract
This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.